At this point, one could speculate that, the combination of the VGF with a panel of different biomarkers [25] perhaps including Cystatin, may constitute a better strategy to aid the diagnosis and prognosis of ALS but also its severity classification, as well as predict its progression. Here, CST4 is linked to amyotrophic lateral sclerosis.